Source link : https://www.newshealth.biz/health-news/outstanding-long-term-t-dm1-data-in-early-breast-cancer/
TOPLINE: One year of adjuvant trastuzumab emtansine (T-DM1) leads to an impressive 5-year invasive disease-free survival rate of 97% among women with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to the final analysis of the ATEMPT trial. METHODOLOGY: Long-term outcomes in patients with early HER2-positive breast cancer treated with adjuvant […]
Author : News Health
Publish date : 2024-07-29 12:23:26
Copyright for syndicated content belongs to the linked Source.
Categories